ICON Past Earnings Performance
Past criteria checks 5/6
ICON has been growing earnings at an average annual rate of 13%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 28.4% per year. ICON's return on equity is 7.2%, and it has net margins of 8.3%.
Key information
13.0%
Earnings growth rate
-0.5%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 28.4% |
Return on equity | 7.2% |
Net Margin | 8.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ICON makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 8,232 | 683 | 754 | 0 |
31 Dec 23 | 8,120 | 612 | 776 | 0 |
30 Sep 23 | 8,016 | 513 | 817 | 0 |
30 Jun 23 | 7,903 | 510 | 797 | 0 |
31 Mar 23 | 7,818 | 510 | 790 | 0 |
31 Dec 22 | 7,741 | 505 | 783 | 0 |
30 Sep 22 | 7,665 | 464 | 758 | 0 |
30 Jun 22 | 7,588 | 210 | 871 | 0 |
31 Mar 22 | 6,524 | 168 | 771 | 0 |
31 Dec 21 | 5,481 | 153 | 662 | 0 |
30 Sep 21 | 4,356 | 178 | 547 | 0 |
30 Jun 21 | 3,191 | 364 | 350 | 0 |
31 Mar 21 | 2,940 | 338 | 344 | 0 |
31 Dec 20 | 2,797 | 328 | 342 | 0 |
30 Sep 20 | 2,762 | 322 | 343 | 0 |
30 Jun 20 | 2,771 | 324 | 345 | 0 |
31 Mar 20 | 2,846 | 368 | 344 | 0 |
31 Dec 19 | 2,806 | 369 | 333 | 0 |
30 Sep 19 | 2,759 | 362 | 336 | 0 |
30 Jun 19 | 2,704 | 353 | 330 | 0 |
31 Mar 19 | 2,651 | 333 | 328 | 0 |
31 Dec 18 | 2,596 | 323 | 326 | 0 |
30 Sep 18 | 2,372 | 306 | 321 | 0 |
30 Jun 18 | 2,157 | 295 | 320 | 0 |
31 Mar 18 | 1,947 | 288 | 326 | 0 |
31 Dec 17 | 1,758 | 281 | 324 | 0 |
30 Sep 17 | 1,738 | 285 | 331 | 0 |
30 Jun 17 | 1,718 | 274 | 333 | 0 |
31 Mar 17 | 1,698 | 271 | 326 | 0 |
31 Dec 16 | 1,666 | 262 | 326 | 0 |
30 Sep 16 | 1,635 | 251 | 326 | 0 |
30 Jun 16 | 1,609 | 249 | 327 | 0 |
31 Mar 16 | 1,587 | 247 | 328 | 0 |
31 Dec 15 | 1,575 | 240 | 327 | 0 |
30 Sep 15 | 1,562 | 221 | 329 | 0 |
30 Jun 15 | 1,555 | 210 | 331 | 0 |
31 Mar 15 | 1,542 | 192 | 337 | 0 |
31 Dec 14 | 1,503 | 172 | 336 | 0 |
30 Sep 14 | 1,458 | 161 | 330 | 0 |
30 Jun 14 | 1,411 | 138 | 327 | 0 |
31 Mar 14 | 1,369 | 120 | 317 | 0 |
31 Dec 13 | 1,336 | 103 | 314 | 0 |
30 Sep 13 | 1,291 | 90 | 308 | 0 |
30 Jun 13 | 1,237 | 80 | 297 | 0 |
Quality Earnings: IJF has high quality earnings.
Growing Profit Margin: IJF's current net profit margins (8.3%) are higher than last year (6.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IJF's earnings have grown by 13% per year over the past 5 years.
Accelerating Growth: IJF's earnings growth over the past year (33.9%) exceeds its 5-year average (13% per year).
Earnings vs Industry: IJF earnings growth over the past year (33.9%) exceeded the Life Sciences industry 6.5%.
Return on Equity
High ROE: IJF's Return on Equity (7.2%) is considered low.